Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma Meeting Abstract
| Authors: | Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Tan, C.; Chung, D.; Landau, H.; Scordo, M.; Hassoun, H.; Maclachlan, K.; Shah, U.; Hultcrantz, M.; Hamadeh, I.; Giralt, S.; Mailankody, S.; Usmani, S.; Hashmi, H. |
| Abstract Title: | Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma |
| Meeting Title: | 21st Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 25-28 |
| Meeting Location: | Rio de Janeiro, Brazil |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S46 |
| Language: | English |
| ACCESSION: | WOS:001325737900074 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)01914-1 |
| Notes: | Meeting Abstract: P-011 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work